Funding
Series A · Biotech

Infinimmune raises $75m Series A for antibody therapeutics

Regeneron Ventures, Playground Global, RA Capital Management and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Infinimmune raised $75 million in Series A financing on August 11. Participants included Regeneron Ventures, Playground Global, RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Merck Global Health Innovation Fund, Everbright Biofund, Wild Tree Ventures, Civilization Ventures and Pear VC.

The company develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease.

Funding history

Series A · This round$75M

Sources

  1. Infinimmuneprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related